A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a

Zivadinov, Robert; Zorzon, Marino; Tommasi, Maria Antonietta; Nasuelli, Davide; Bernardi, Monica; Monti-Bragadin, Luisa; Cazzato, Giuseppe

doi:10.1016/s0022-510x(03)00225-9

Cited by 74 publications

(41 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, there is no therapy for other neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, and amytrophic lateral sclerosis (ALS). Patients with multiple sclerosis (MS) are treated with cytokines that work on the peripheral immune system, but which do not permanently stop the progression of MS. 3 The human immunodeficiency virus (HIV) infects the brain early in the course of acquired immune deficiency syndrome (AIDS). 4 HIV in the periphery has been significantly reduced with highly active antiretroviral therapy (HAART) comprised of multiple small-molecule therapeutics.…”

Section: Introductionmentioning

confidence: 99%

The blood-brain barrier: Bottleneck in brain drug development

Pardridge¹

2005

Neurotherapeutics

2,152

1,159

View full text Add to dashboard Cite

Summary:The blood-brain barrier (BBB) is formed by the brain capillary endothelium and excludes from the brain ϳ100% of large-molecule neurotherapeutics and more than 98% of all small-molecule drugs. Despite the importance of the BBB to the neurotherapeutics mission, the BBB receives insufficient attention in either academic neuroscience or industry programs. The combination of so little effort in developing solutions to the BBB problem, and the minimal BBB transport of the majority of all potential CNS drugs, leads predictably to the present situation in neurotherapeutics, which is that there are few effective treatments for the majority of CNS disorders. This situation can be reversed by an accelerated effort to develop a knowledge base in the fundamental transport properties of the BBB, and the molecular and cellular biology of the brain capillary endothelium. This provides the platform for CNS drug delivery programs, which should be developed in parallel with traditional CNS drug discovery efforts in the molecular neurosciences.

show abstract

Section: Introductionmentioning

confidence: 99%

The blood-brain barrier: Bottleneck in brain drug development

Pardridge¹

2005

Neurotherapeutics

2,152

1,159

View full text Add to dashboard Cite

show abstract

“…2,3 Motor and cognitive impairment, fatigue, depression, pain, incontinence, sexual dysfunction, and the unpredictability of the disease reduce health-related quality of life [4][5][6][7][8][9][10][11] and participation in work and life. 2,12,13 Although it has been difficult to show the effect of multidisciplinary rehabilitation stays in clinical trials, 14,15 several studies have suggested a positive effect of multidisciplinary rehabilitation on disability [15][16][17][18][19][20][21] and aspects of health-related quality of life.…”

mentioning

confidence: 99%

Barriers and Facilitators Related to Rehabilitation Stays in Multiple Sclerosis

Helland

Holmøy

Gulbrandsen³

2015

International Journal of MS Care

View full text Add to dashboard Cite

show abstract

“…These instruments include the Functional Independence Measure (FIM) scale, a 30-minute assessment of physical and cognitive disability that focuses on the level of patient disability as an indicator of the burden of care; the Symbol Digit Modalities Test (SDMT), a 5-minute assessment that screens the participant for any kind of cerebral dysfunction using a simple substitution task; and the Paced Auditory Serial Addition Test (PASAT), a validated, 15-minute tool that evaluates a patient's sustained attention, working memory, and speed of information processing. [9][10][11][12] In addition, the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) was recently developed by an international committee as a brief cognitive assessment for MS that is optimized for small centers. 13 A validation protocol has been prepared for regional language groups, and validation studies for BICAMS are underway.…”

Section: ■■ Measures Of Disability: Cognition and The Ms Functional Cmentioning

confidence: 99%

“…of IM IFNβ-1a therapy in patients with clinically isolated syndrome (CIS). 15 Analysis of PASAT scores obtained during study years [5][6][7][8][9][10] showed that more than 95% of the patients followed in CHAMPIONS 10 and treated with IM IFNβ-1a remained cognitively stable over this span. 15 However, data from serial cognitive assessments must be interpreted with caution because of the potential for practice effects resulting from test repetition to influence results.…”

Section: ■■ Measures Of Disability: Cognition and The Ms Functional Cmentioning

confidence: 99%

Emerging Methods for Evaluating the Effectiveness of Intramuscular Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis

Foley¹,

Barnes²,

Nair³

2013

JMCP

View full text Add to dashboard Cite

Newer outcome-based assessment methods have been developed that complement and improve upon the ability of historical clinical and magnetic resonance imaging (MRI) outcome measures to measure multiple sclerosis (MS) disease activity, patient functionality, treatment efficacy, and the risk of MS disease progression. These newer MS outcome assessments include instruments to evaluate cognitive function and patient quality of life; enhanced measures of disability, such as the Multiple Sclerosis Functional Composite instrument; and newer MRI measures of MS disease activity and neuronal changes, such as permanent T 1 hypointensities and central nervous system atrophy. When utilized in conjunction with standard MS outcome measures, these newer MS outcomes provide a more comprehensive picture of disease status and course and hold promise as tools for use in the development and testing of future MS therapies. The well-established first-line MS therapy intramuscular interferon beta-1a, which has been evaluated using a broad range of assessment methods, was used as a reference MS disease-modifying therapy to provide specific examples of studies utilizing newer evaluation methods. Utilization of evolving disease and assessment measures for patients with MS should improve MS patient diagnosis, treatment decisions, and monitoring of therapy. • Multiple sclerosis (MS) is a chronic, immune-mediated neurologic disease that is associated with progressive patient disability and diminished quality of life (QoL).• Historical clinical outcomes, such as MS relapses, physical disability measures, and magnetic resonance imaging (MRI) endpoints, do not capture important elements of MS, such as the impact of MS and MS therapies on a patient's perceived QoL.• This article provides an overview of several key newer MS patient outcomes, including instruments used to assess MS patient cognition, QoL, composite disability measures, and emerging MRI clinical endpoints.• Newer MS patient outcomes have the potential to improve MS patient care and the development and testing of future therapeutics for the treatment of MS. Summary Points Presented in this ArticleHowever, older measures do not capture the entire impact of the disease (e.g., cognition, upper limb function, etc.) on patient function and well-being. Newer outcome measures are being developed with the purpose of capturing additional aspects of the disease and facilitating a more comprehensive assessment of MS disability, progression, and therapeutic efficacy. The primary purpose of this article is to provide the managed care audience with an overview of the most prominent newer MS measures. The potential benefits of these newer outcomes are illustrated using published clinical data on intramuscular interferon beta-1a (IM IFNβ-1a) as an extensively evaluated, representative first-line MS therapy.

show abstract

A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a

Cited by 74 publications

References 23 publications

The blood-brain barrier: Bottleneck in brain drug development

The blood-brain barrier: Bottleneck in brain drug development

Barriers and Facilitators Related to Rehabilitation Stays in Multiple Sclerosis

Emerging Methods for Evaluating the Effectiveness of Intramuscular Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis

Contact Info

Product

Resources

About